LOXL2
Lysyl oxidase homolog 2
As of the edition of 20 October 2026, LOXL2 (lysyl oxidase homolog 2, UniProt Q9Y4K0) has 2 drugs tested at it and 2 companies on the list, 2 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9Y4K0
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 1
- Disease areas
- Digestive system; Cancer; Lungs and airways; Blood and lymph; Hormones; Infections
- Registered trials of its drugs
- 15
Drugs at this target
| Status | Count |
|---|---|
| Stopped | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Simtuzumab | Stopped | Phase 2 | none listed |
| Lenumlostat | Stopped | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| Galecto | Route A |
| Gilead Sciences | Route A |
The other 0 companies at LOXL2
In the product2 companies in all; 0 are not named here, and no score is.
See the 2 companies at LOXL2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.